The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Prevention of Islet Allograft Rejection with Engineered Myoblasts Expressing FasL in Mice
Abstract
Allogeneic transplantation of islets of Langerhans was facilitated by the cotransplantation of syngeneic myoblasts genetically engineered to express the Fas ligand (FasL). Composite grafting of allogeneic islets with syngeneic myoblasts expressing FasL protected the islet graft from immune rejection and maintained normoglycemia for more than 80 days in mice with streptozotocin-induced diabetes. Graft survival was not prolonged with composite grafts of unmodified myoblasts or Fas-expressing myoblasts. Islet allografts transplanted separately from FasL-expressing myoblasts into the contralateral kidney were rejected, as were similarly transplanted third-party thyroid allografts. Thus, the FasL signal provided site- and immune-specific protection of islet allografts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
Gavrieli, Y., Sherman, Y., & Ben-Sasson, S. A. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.493 · Cited by 9,444
Apoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524
Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege
Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., & Ferguson, T. A. (1995) · Science · doi:10.1126/science.270.5239.1189 · Cited by 2,005
Lethal effect of the anti-Fas antibody in mice
Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., & Nagata, S. (1993) · Nature · doi:10.1038/364806a0 · Cited by 1,881
A role for CD95 ligand in preventing graft rejection
Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A., & Duke, R. C. (1995) · Nature · doi:10.1038/377630a0 · Cited by 1,155
Rando, T. A., & Blau, H. M. (1994) · The Journal of cell biology · doi:10.1083/jcb.125.6.1275 · Cited by 936
Leithäuser, F., Dhein, J., Mechtersheimer, G., Koretz, K., Brüderlein, S., Henne, C., Schmidt, A., Debatin, K., Krammer, P. H., & Möller, P. (1993) · PubMed · Cited by 625
Fas and FasL in the homeostatic regulation of immune responses
Lynch, D. H., Ramsdell, F., & Alderson, M. R. (1995) · Immunology Today · doi:10.1016/0167-5699(95)80079-4 · Cited by 558
Purification and characterization of the Fas-ligand that induces apoptosis.
Suda, T., & Nagata, S. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.3.873 · Cited by 507
Fas and Fas Ligand: A Death Factor and Its Receptor
Nagata, S. (1994) · Advances in Immunology · doi:10.1016/s0065-2776(08)60672-0 · Cited by 338
Cited by
Nagata, S. (1997) · Cell · doi:10.1016/s0092-8674(00)81874-7 · Cited by 4,938
Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape
Hahne, M., Rimoldi, D., Schröter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., et al. (1996) · Science · doi:10.1126/science.274.5291.1363 · Cited by 1,249
Self-citationMaldonado-López, R., De Smedt, T., Michel, P., Godfroid, J., Pajak, B., Heirman, C., Thielemans, K., Leo, O., Urbain, J., & Moser, M. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.3.587 · Cited by 984
MATURE T LYMPHOCYTE APOPTOSIS—Immune Regulation in a Dynamic and Unpredictable Antigenic Environment
Lenardo, M., Chan, F. K.-M., Hornung, F., McFarland, H., Siegel, R., Wang, J., & Zheng, L. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.221 · Cited by 943
Nagata, S. (1999) · Annual Review of Genetics · doi:10.1146/annurev.genet.33.1.29 · Cited by 779
Downregulation of Fas ligand by shedding
Tanaka, M., Itai, T., Adachi, M., & Nagata, S. (1998) · Nature Medicine · doi:10.1038/nm0198-031 · Cited by 669
The Fas System Is a Key Regulator of Germ Cell Apoptosis in the Testis*
Lee, J., Richburg, J. H., Younkin, S. C., & Boekelheide, K. (1997) · Endocrinology · doi:10.1210/endo.138.5.5110 · Cited by 519
To Die or Not to Die: An Overview of Apoptosis and Its Role in Disease
Hetts, S. W. (1998) · JAMA · doi:10.1001/jama.279.4.300 · Cited by 507
Death receptors in chemotherapy and cancer
Debatin, K.-M., & Krammer, P. H. (2004) · Oncogene · doi:10.1038/sj.onc.1207558 · Cited by 505
The Role of Fas in Autoimmune Diabetes
Chervonsky, A. V., Wang, Y., Wong, F. S., Visintin, I., Flavell, R. A., Janeway, C. A., & Matis, L. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80178-6 · Cited by 496
Immune escape of tumors: apoptosis resistance and tumor counterattack
Igney, F. H., & Krammer, P. H. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.6.907 · Cited by 468
Kang, S.-M., Schneider, D. B., Lin, Z., Hanahan, D., Dichek, D. A., Stock, P. G., & Baekkeskov, S. (1997) · Nature Medicine · doi:10.1038/nm0797-738 · Cited by 450
Advances in islet encapsulation technologies
Desai, T., & Shea, L. D. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.232 · Cited by 427
Metal Activation of Enzymes in Nucleic Acid Biochemistry
Cowan, J. A. (1998) · Chemical Reviews · doi:10.1021/cr960436q · Cited by 406
Regulation of the Proinflammatory Effects of Fas Ligand (CD95L)
Chen, J.-J., Sun, Y., & Nabel, G. J. (1998) · Science · doi:10.1126/science.282.5394.1714 · Cited by 383
Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand
Miwa, K., Asano, M., Horai, R., Iwakura, Y., Nagata, S., & Suda, T. (1998) · Nature Medicine · doi:10.1038/3276 · Cited by 373
CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival.
Stuart, P. M., Griffith, T. S., Usui, N., Pepose, J., Yu, X., & Ferguson, T. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119173 · Cited by 367
Allison, J., Georgiou, H. M., Strasser, A., & Vaux, D. L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3943 · Cited by 366
Bennett, M. W., O’Connell, J., O’Sullivan, G. C., Brady, C., Roche, D., Collins, J. K., & Shanahan, F. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.11.5669 · Cited by 326
Hierarchical Control of Lymphocyte Survival
Boise, L. H., & Thompson, C. B. (1996) · Science · doi:10.1126/science.274.5284.67 · Cited by 253
The role of FasL-induced apoptosis in immune privilege
Griffith, T. S., & Ferguson, T. A. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)81663-5 · Cited by 253
The Fas counterattack: Cancer as a site of immune privilege
O’Connell, J., Bennett, M. W., O’Sullivan, G. C., Collins, J. K., & Shanahan, F. (1999) · Immunology Today · doi:10.1016/s0167-5699(98)01382-6 · Cited by 232
Headen, D. M., Woodward, K. B., Coronel, M. M., Shrestha, P., Weaver, J. D., Zhao, H., Tan, M., Hunckler, M. D., Bowen, W. S., Johnson, C. T., et al. (2018) · Nature Materials · doi:10.1038/s41563-018-0099-0 · Cited by 175
Tumor counterattack: Fact or fiction?
Igney, F. H., & Krammer, P. H. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0680-7 · Cited by 98
Yolcu, E. S., Zhao, H., Bandura-Morgan, L., Lacelle, C., Woodward, K. B., Askenasy, N., & Shirwan, H. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003266 · Cited by 82
FasL microgels induce immune acceptance of islet allografts in nonhuman primates
Lei, J., Coronel, M. M., Yolcu, E. S., Deng, H., Grimany-Nuno, O., Hunckler, M. D., Ulker, V., Yang, Z., Lee, K. M., Zhang, A., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm9881 · Cited by 77
Myoblast-mediated gene transfer to the joint
Day, C. S., Kasemkijwattana, C., Menetrey, J., Floyd, S. S., Booth, D., Moreland, M. S., Fu, F. H., & Huard, J. (1997) · Journal of Orthopaedic Research · doi:10.1002/jor.1100150616 · Cited by 66
Wang, X., Wang, K., Yu, M., Velluto, D., Hong, X., Wang, B., Chiu, A., Melero-Martin, J. M., Tomei, A. A., & Ma, M. (2022) · Science Advances · doi:10.1126/sciadv.abn0071 · Cited by 62
Self-citationWoodward, K. B., Zhao, H., Shrestha, P., Batra, L., Tan, M., Grimany-Nuno, O., Bandura-Morgan, L., Askenasy, N., Shirwan, H., & Yolcu, E. S. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15747 · Cited by 35
Metadata
- Authors
- Lau, H. T., Yu, M., Fontana, A., & Stoeckert, C. J.
- Venue
- Science
- Published
- 1996-07-05
- Volume
- 273
- Issue
- 5271
- Pages
- 109-112
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2078901980
- Cited by
- 445
- References
- 17
- FWCI
- 84.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.